BOSTON--(BUSINESS WIRE)--May 31, 2017--
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing
drugs to improve the survival and quality of life of cancer patients,
today announced that the company will present at the Jefferies 2017
Global Healthcare Conference on Friday, June 9 at 11:00 a.m. ET at the
Grand Hyatt in New York City.
A live audio webcast of the presentation will be available on the
company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
PI3K-delta and PI3K-gamma, which has successfully met its primary
endpoint in a Phase 2 study in iNHL and is currently being evaluated in
a Phase 3 clinical trial in patients with CLL. In addition, Verastem is
developing the FAK inhibitor defactinib, which is currently being
evaluated in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small cell lung
cancer, and mesothelioma. Verastem’s product candidates seek to treat
cancer by modulating the local tumor microenvironment, enhancing
anti-tumor immunity and reducing cancer stem cells. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005277/en/
Source: Verastem, Inc.
Verastem, Inc.
Brian Sullivan, 781-292-4214
Director,
Corporate Development
bsullivan@verastem.com
